Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.

摘要: Background and aims Extraintestinal manifestations [EIMs] such as arthritis/arthralgia are common in inflammatory bowel disease. We performed post hoc analyses of data from the GEMINI studies to evaluate effect vedolizumab, a gut-selective anti-trafficking agent, on arthritis/arthralgia. Methods Sustained resolution baseline arthritis/arthralgia, worsening occurrence new composite new/worsening were evaluated. Cox modelling was used for time-to-event analysis. The influence corticosteroid-tapering also investigated. Results In Crohn's disease [CD] patients, vedolizumab significantly less likely than placebo be associated with (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.44-0.89). Similar incidences sustained occurred placebo. CD patients corticosteroids at baseline, decrease corticosteroid dose increased risk (odds [OR], 7.49; CI, 3.50-15.97) regardless treatment; those achieving corticosteroid-free status, [HR, 0.14; 0.05-0.35]. ulcerative colitis [UC] showed similar incidence UC more status continuing (HR 2.63 [95% CI 1.13-6.11]); Conclusions Vedolizumab therapy reduced likelihood no these events UC. Studies included [clincialtrials.gov, number] 1 [NCT00783718]; 2 [NCT00783692]; 3 [NCT01224171].